CoChat

Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model

Open access

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

Pharmacological treatments for non-alcoholic steatohepatitis (NASH) are still unsatisfactory. Fibrosis is the most significant predictor of mortality and many anti-fibrotic agents are under evaluation. Herein, we assessed in vitro the effects of the FXR agonist obeticholic acid (OCA) and the dual FXR/TGR5 agonist INT-767 in a well-established co-culture NASH model. Co-cultures of human hepatoma and hepatic stellate (HSCs) cells were exposed to free fatty acids (FFAs) alone or in combination with OCA or INT-767. mRNA expression of HSCs activation markers and FXR engagement were evaluated at 24, 96 and 144 hours. Collagen deposition and metalloproteinase 2 and 9 (MMP2-9) activity were compared to tropifexor and selonsertib. FFAs induced collagen deposition and MMP2-9 activity reduction. Co-treatment with OCA or INT-767 did not affect ACTA2 and COL1A1 expression, but significantly reduced FXR and induced SHP expression, as expected. OCA induced a dose-dependent reduction of collagen and induced MMP2-9 activity. Similarly, INT-767 induced collagen reduction at 96 h and a slight increase in MMP2-9. Tropifexor and Selonsertib were also effective in collagen reduction but showed no modulation of MMP2-9. All tested compounds reduced collagen deposition. OCA exerted a more potent and long-lasting effect, mainly related to modulation of collagen turn-over and MMP2-9 activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-020-58562-x

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Dose-response curves for OCA and INT-767. (a) Simultaneous co-cultures (SCC) were treated with increasing concentrations of OCA (left panel) or INT-767 (right panel) with (full line) or without (dashed line) FFAs for 144 hours. Monocultures of hepatocytes (b) and HSCs (c) were treated with the selected concentrations of OCA (left panel) or INT-767 (right panel) with (full line) or without (dashed line) FFAs for 144 hours. Horizontal dashed bars indicate the cutoff. Data is represented as mean ± SD of at least three independent biological replicates.
Figure 1 Dose-response curves for OCA and INT-767. (a) Simultaneous co-cultures (SCC) were treated with increasing concentrations of OCA (left panel) or INT-767 (right panel) with (full line) or without (dashed line) FFAs for 144 hours. Monocultures of hepatocytes (b) and HSCs (c) were treated with the selected concentrations of OCA (left panel) or INT-767 (right panel) with (full line) or without (dashed line) FFAs for 144 hours. Horizontal dashed bars indicate the cutoff. Data is represented as mean ± SD of at least three independent biological replicates.CC BY · PubMed Central
Figure 2 Activation of HSCs. (a) ACTA2 mRNA expression upon FFAs exposure vs. CTRL. (b) ACTA2 expression following treatment with FFAs and FXR agonists vs. FFAs (dashed bar). (c) ACTA2 expression following OCA and INT-767 treatment vs. CTRL (dashed line). Data is represented as mean ± SD of at least three independent biological replicates. *p < 0.05; **p < 0.01 vs. FFAs (b) or CTRL (c).
Figure 2 Activation of HSCs. (a) ACTA2 mRNA expression upon FFAs exposure vs. CTRL. (b) ACTA2 expression following treatment with FFAs and FXR agonists vs. FFAs (dashed bar). (c) ACTA2 expression following OCA and INT-767 treatment vs. CTRL (dashed line). Data is represented as mean ± SD of at least three independent biological replicates. *p < 0.05; **p < 0.01 vs. FFAs (b) or CTRL (c).CC BY · PubMed Central
Figure 3 Collagen biosynthesis. (a) Col1A1 gene expression upon FFAs exposure vs. CTRL (dashed bar). (b) Col1A1 mRNA expression following treatment with FFAs and FXR agonists vs. FFAs (dashed bar). (c) Quantification of extracellular COL1A1 deposition upon FFAs exposure vs. CTRL (dashed bar). (d) Quantification of extracellular COL1A1 deposition following treatment with FFAs and FXR agonists vs. FFAs (dashed line). (e) Col1A1 gene expression upon FXR agonists treatment vs. CTRL (dashed line). (f) Quantification extracellular COL1A1 deposition upon FXR agonists treatment vs. CTRL (dashed line). Data is represented as mean ± SD of at least three independent biological replicates. *p < 0.05; **p < 0.01 vs. FFAs (b–d) or CTRL (A-C-E-F).
Figure 3 Collagen biosynthesis. (a) Col1A1 gene expression upon FFAs exposure vs. CTRL (dashed bar). (b) Col1A1 mRNA expression following treatment with FFAs and FXR agonists vs. FFAs (dashed bar). (c) Quantification of extracellular COL1A1 deposition upon FFAs exposure vs. CTRL (dashed bar). (d) Quantification of extracellular COL1A1 deposition following treatment with FFAs and FXR agonists vs. FFAs (dashed line). (e) Col1A1 gene expression upon FXR agonists treatment vs. CTRL (dashed line). (f) Quantification extracellular COL1A1 deposition upon FXR agonists treatment vs. CTRL (dashed line). Data is represented as mean ± SD of at least three independent biological replicates. *p < 0.05; **p < 0.01 vs. FFAs (b–d) or CTRL (A-C-E-F).CC BY · PubMed Central
Figure 4 MMP2-9 activity. Enzymatic activity of active MMP2-9 was analyzed in the supernatant of SCC treated with FFAs and FXR agonist compounds after (a) 96 and (b) 144 hours of treatment. Activity was normalized to the total proteins in the cell lysate and reported as percentage vs. FFAs treated sample. Data is represented as mean ± SD of at least three independent biological replicates. *p < 0.05 vs. FFAs; #p < 0.05 vs. CTRL.
Figure 4 MMP2-9 activity. Enzymatic activity of active MMP2-9 was analyzed in the supernatant of SCC treated with FFAs and FXR agonist compounds after (a) 96 and (b) 144 hours of treatment. Activity was normalized to the total proteins in the cell lysate and reported as percentage vs. FFAs treated sample. Data is represented as mean ± SD of at least three independent biological replicates. *p < 0.05 vs. FFAs; #p < 0.05 vs. CTRL.CC BY · PubMed Central
Figure 5 FXR pathway gene analysis. (a) FXR and SHP gene expression upon FFAs exposure vs. CTRL. (b) FXR gene expression upon FFAs and FXR agonists treatment vs. FFAs (dashed bar). (c) SHP gene expression upon FFAs and FXR agonists treatment vs. FFAs (dashed line). (d) FXR gene expression upon OCA and INT-767 treatment vs. CTRL (dashed line) (e) SHP gene expression upon OCA and INT-767 treatment vs. CTRL (dashed line). Data is represented as mean ± SD of at least three independent biological replicates. *p < 0.05; **p < 0.01 vs. FFAs (b,c) or CTRL (A-C-D).
Figure 5 FXR pathway gene analysis. (a) FXR and SHP gene expression upon FFAs exposure vs. CTRL. (b) FXR gene expression upon FFAs and FXR agonists treatment vs. FFAs (dashed bar). (c) SHP gene expression upon FFAs and FXR agonists treatment vs. FFAs (dashed line). (d) FXR gene expression upon OCA and INT-767 treatment vs. CTRL (dashed line) (e) SHP gene expression upon OCA and INT-767 treatment vs. CTRL (dashed line). Data is represented as mean ± SD of at least three independent biological replicates. *p < 0.05; **p < 0.01 vs. FFAs (b,c) or CTRL (A-C-D).CC BY · PubMed Central
Figure 6 Dose-response curves for tropifexor and selonsertib. Simultaneous co-cultures were treated with increasing concentrations of tropifexor (a) or selonsertib (b) with (full line) or without (dashed line) FFAs for 144 hours. Horizontal dashed bars indicate the cutoff. Data is represented as mean ± SD of at least three independent biological replicates.
Figure 6 Dose-response curves for tropifexor and selonsertib. Simultaneous co-cultures were treated with increasing concentrations of tropifexor (a) or selonsertib (b) with (full line) or without (dashed line) FFAs for 144 hours. Horizontal dashed bars indicate the cutoff. Data is represented as mean ± SD of at least three independent biological replicates.CC BY · PubMed Central
Figure 7 Collagen turnover upon tropifexor or selonsertib treatment. (a) Extracellular quantification of the total collagen upon FFAs and FXR agonists treatment vs. FFAs (dashed line). (b) or upon FXR agonists treatment vs. CTRL (dashed line). (c) Active MMP2-9 was quantified in the supernatant of SCC treated with FFAs and FXR agonists after 96 and 144 hours. Activity was normalized to the total proteins in the cell lysate and reported as percentage vs. FFAs treated sample. Data is represented as mean ± SD of at least three independent biological replicates. *p < 0.05; **p < 0.01 vs. FFAs (a) or CTRL (b).
Figure 7 Collagen turnover upon tropifexor or selonsertib treatment. (a) Extracellular quantification of the total collagen upon FFAs and FXR agonists treatment vs. FFAs (dashed line). (b) or upon FXR agonists treatment vs. CTRL (dashed line). (c) Active MMP2-9 was quantified in the supernatant of SCC treated with FFAs and FXR agonists after 96 and 144 hours. Activity was normalized to the total proteins in the cell lysate and reported as percentage vs. FFAs treated sample. Data is represented as mean ± SD of at least three independent biological replicates. *p < 0.05; **p < 0.01 vs. FFAs (a) or CTRL (b).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 41 references

Research works printed but not linked: 1

  1. https://www.gilead.com/news-and-press/press-room/press-releases/2019/2/gilead-announces-topline-data-from-phase-3-stellar4-study-of-selonsertib-in-compensated-cirrhosis-f4-due-to-nonalcoholic-steatohepatitis-nash (2019).

Cited by

See all 44

Metadata

Authors
Anfuso, B., Tiribelli, C., Adorini, L., & Rosso, N.
Affiliations
  • AREA Science Park (IT)
  • Intercept Pharmaceuticals (United States) (US)
Corresponding author
Rosso, Natalia
Venue
Scientific Reports
Published
2020-02-03
Volume
10
Issue
1
Pages
1699-1699
ISSN
2045-2322 (ISSN-L)
OpenAlex
W3004413824
Cited by
43
References
41
Citations by year
2026: 2 · 2025: 7 · 2024: 10 · 2023: 7 · 2022: 8 · 2021: 5 · 2020: 4
FWCI
4.30
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Intercept Pharmaceuticals
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords
obeticholic acid, nonalcoholic steatohepatitis, liver fibrosis, collagen deposition, hepatic stellate cells, FXR agonists, TGR5 agonists, free fatty acids, matrix metalloproteinases, selonsertib, antifibrotic therapy
MeSH terms
Benzamides, Bile Acids and Salts, Cell Line, Chenodeoxycholic Acid, Collagen, Fatty Acids, Nonesterified, Humans, Imidazoles, Isoxazoles, Liver, Pyridines, RNA-Binding Proteins, Receptors, Cytoplasmic and Nuclear, Coculture Techniques, Matrix Metalloproteinase 2, Matrix Metalloproteinase 9, Hepatocytes, Protein Kinase Inhibitors, Benzothiazoles, Hepatic Stellate Cells, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model. https://app.cochat.ai/papers/10.1038/s41598-020-58562-x
The paper
Anfuso, B., Tiribelli, C., Adorini, L., & Rosso, N. (2020). Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model. Scientific Reports. https://doi.org/10.1038/s41598-020-58562-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.